 PRINCETON, N.J., Dec. 22, 2020 GLOBE NEWSWIRE -- Advaxis, Inc. Nasdaq: ADXS, a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it received a positive determination from the Nasdaq Stock Market granting approval of the Companys request to transfer its listing to the Nasdaq Capital Market from the Nasdaq Global Select Market. The Companys securities will begin trading on the Nasdaq Capital Market effective at the start of trading on December 24, 2020. The Companys shares will continue to trade on Nasdaq under the symbol ADXS. 